Try our beta test site
1901 studies found for:    "Melanoma"
Show Display Options
RSS Create an RSS feed from your search for:
"Melanoma"
Need help? See RSS Feeds
Choose a feed type:
Show studies that were first received in the last 14 daysShow studies that were first received in the last 14 days
Show studies added or modified in the last 14 daysShow studies that were added or modified in the last 14 days
Rank Status Study
1 Recruiting Prospective Melanoma Database
Condition: Melanoma
Intervention: Other: clinical biological data collection on melanoma
2 Completed EF5 in Melanoma Patients
Condition: Melanoma
Intervention: Drug: EF5 Hypoxia
3 Recruiting Characterization of the Melanoma-Specific Immune Response
Condition: Melanoma
Intervention:
4 Terminated Early Diagnosis of Melanoma Using Expression Profiling and Non-Invasive Sampling of Skin Cells
Condition: Melanoma
Intervention: Other: EGIR Tape
5 Recruiting Diagnostic Imaging Study for the Melanoma Advanced Imaging Dermatoscope (mAID)
Condition: Melanoma
Intervention:
6 Terminated Safety Study of Human IgM (MORAb-028) to Treat Metastatic Melanoma
Condition: Melanoma
Intervention: Drug: MORAb028
7 Active, not recruiting Ipilimumab and All-Trans Retinoic Acid Combination Treatment of Stage IV Melanoma
Condition: Melanoma
Interventions: Drug: All-Trans Retinoic Acid;   Drug: Ipilimumab
8 Completed
Has Results
Melanoma Perception and Health Literacy in People of Color
Condition: Melanoma
Interventions: Behavioral: ABCDEs of Melanoma Skin Cancer;   Behavioral: ABCDEs of Melanoma
9 Recruiting A Clinical Trial of Patients With Melanoma
Condition: Melanoma
Interventions: Drug: Digoxin Combination;   Drug: Dabrafenib;   Drug: Trametinib
10 Completed Haploidentical NK Cell Infusion in Malignant Melanoma
Condition: Melanoma
Intervention: Biological: Haploidentical NK cell
11 Active, not recruiting Vaccination Plus Ontak in Patients With Metastatic Melanoma
Condition: Melanoma
Interventions: Drug: 4-peptide melanoma vaccine;   Drug: 4-peptide melanoma vaccine plus Ontak;   Drug: ontak
12 Completed Vaccine Therapy in Treating Patients With Stage IV or Relapsed Malignant Melanoma
Condition: Melanoma
Interventions: Biological: dendritic cell-MART-1 peptide vaccine;   Procedure: leukapheresis
13 Terminated Vaccination of Melanoma Patients With Total or CD25-depleted Peripheral Blood Mononuclear Cell (PBMC)
Condition: Melanoma
Interventions: Biological: PBMC re-infusion;   Biological: CD25 depletion
14 Completed Evaluate Safety/Tolerability Intra-Arterial Temozolomide in Patients w/Extremity Melanoma by Isolated Limb Infusion
Condition: Melanoma
Intervention: Drug: Temozolomide
15 Completed
Has Results
Erlotinib and Bevacizumab in Treating Patients With Stage IV Melanoma
Condition: Melanoma
Interventions: Biological: bevacizumab;   Drug: erlotinib hydrochloride;   Genetic: fluorescence in situ hybridization;   Genetic: gene expression analysis;   Other: immunologic technique;   Other: laboratory biomarker analysis;   Procedure: biopsy
16 Completed
Has Results
Temozolomide Versus Dacarbazine in Stage IV Metastatic Melanoma (Study P03267)
Condition: Melanoma
Interventions: Drug: Temozolomide;   Drug: Dacarbazine
17 Active, not recruiting LGX818 and MEK162 in Combination With a Third Agent (BKM120, LEE011, BGJ398 or INC280) in Advanced BRAF Melanoma
Condition: Melanoma
Interventions: Drug: LGX818;   Drug: MEK162;   Drug: LEE011;   Drug: BGJ398;   Drug: BKM120;   Drug: INC280
18 Recruiting A Phase I/II Trial of Vemurafenib and Metformin to Melanoma Patients
Condition: Melanoma
Interventions: Drug: Vemurafenib;   Drug: Metformin
19 Recruiting Study Assessing Two Models of Hypofractionated Protontherapy on Large Choroidal Melanomas
Condition: Melanoma
Intervention: Radiation: Protontherapy
20 Terminated Imatinib in Adult Patients With Metastatic Ocular Melanoma
Condition: Melanoma
Intervention: Drug: Imatinib

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.